ELI LILLY & CO (LLY.DE) Stock Price, Forecast & Analysis
FRA:LLY • US5324571083
LLY.DE Key Statistics, Chart & Performance
The current stock price of LLY.DE is 883.2 EUR. In the past month the price decreased by -1.99%. In the past year, price increased by 7.68%.
LLY.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LLY.DE. When comparing the yearly performance of all stocks, LLY.DE turns out to be only a medium performer in the overall market: it outperformed 51.55% of all stocks.
LLY.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LLY.DE. LLY.DE scores excellent on profitability, but there are some minor concerns on its financial health.
LLY.DE Financial Highlights
Over the last trailing twelve months LLY.DE reported a non-GAAP Earnings per Share(EPS) of 20.39. The EPS increased by 86.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.99% | ||
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| Debt/Equity | 1.72 |
LLY.DE Forecast & Estimates
37 analysts have analysed LLY.DE and the average price target is 994.71 EUR. This implies a price increase of 12.63% is expected in the next year compared to the current price of 883.2.
For the next year, analysts expect an EPS growth of 38.64% and a revenue growth 21.61% for LLY.DE
LLY.DE Ownership
LLY.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.76 | 199.188B | ||
| SNW | SANOFI | 9.39 | 191.629B | ||
| SAN | SANOFI | 9.18 | 191.049B | ||
| MRK | MERCK KGAA | 14.87 | 54.521B | ||
| UCB | UCB SA | 27.18 | 53.237B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UNC | UCB SA | 26.19 | 52.381B | ||
| 1BAYN | BAYER AG-REG | 9.42 | 45.191B | ||
| BAYN | BAYER AG-REG | 9.41 | 44.887B | ||
| IPN | IPSEN | 13.47 | 12.37B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About LLY.DE
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 47000
Phone: 13172762000
ELI LILLY & CO / LLY.DE FAQ
Can you describe the business of ELI LILLY & CO?
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
What is the stock price of ELI LILLY & CO today?
The current stock price of LLY.DE is 883.2 EUR. The price increased by 1.16% in the last trading session.
Does LLY stock pay dividends?
ELI LILLY & CO (LLY.DE) has a dividend yield of 0.68%. The yearly dividend amount is currently 4.18.
What is the ChartMill rating of ELI LILLY & CO stock?
LLY.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ELI LILLY & CO (LLY.DE) expected to grow?
The Revenue of ELI LILLY & CO (LLY.DE) is expected to grow by 21.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of ELI LILLY & CO (LLY.DE)?
You can find the ownership structure of ELI LILLY & CO (LLY.DE) on the Ownership tab.